Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

Revenue projections:

Revenue projections for SUVENPHAR
Revenue projections for SUVENPHAR

With Suven Pharmaceuticals Limited's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.269436
debtToEquity 1.945000
earningsGrowth 0.755000
revenueGrowth 0.397000
grossMargins 0.627760
operatingMargins 0.316950
trailingEps 10.900000
forwardEps 0.000000

SUVENPHAR's forward PE is too high, signaling potential overvaluation. This could cap future price increases and trigger a correction. Investors should carefully analyze this metric along with other fundamental indicators before making investment decisions.
Suven Pharmaceuticals Limited's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with Suven Pharmaceuticals Limited expected to continue increasing its profits and revenue in the coming periods.
SUVENPHAR's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.

Price projections:

Price projections for SUVENPHAR
Price projections for SUVENPHAR

SUVENPHAR's current price does not reveal any distinct risks or opportunities compared to its projections. This neutral assessment suggests stability, where investors might choose to retain their current positions until future developments warrant a reassessment.

Recommendation changes over time:

Recommendations trend for SUVENPHAR
Recommendations trend for SUVENPHAR


SUVENPHAR has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view SUVENPHAR as a reliable choice for their money, offering a promising avenue for future growth and financial gains.